Ozmosis Research

Name

Ozmosis Research

Legal name

Ozmosis Research Inc.

Website

https://ozmosisresearch.ca

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Clinical Trial Site Operations & Study Coordination (HLAGACAE)

Keywords

• Clinical trial management
• Oncology research services
• Contract research organization
• Drug development services
• Clinical data management

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Clinical Trial Management Services: Ozmosis Research generates revenue through professional services contracts with pharmaceutical companies, biotechnology companies, academic institutions, and investigators. Services include clinical trial management, site management, monitoring, regulatory services, data management, and medical services. The company is a social enterprise (not for profit) Ontario Corporation that invests profits into research.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Ozmosis Research is a full-service Clinical Trials Management Company (CRO) providing end-to-end oncology clinical trial services across Phase I, II, and III studies. The company offers concept development, project and site management, regulatory services, medical monitoring, on-site monitoring, quality assurance, and electronic data capture via its accredited Medidata Rave EDC partnership. Services are customized to sponsor needs and span drug development from study design through to analysis.

Product overview

Ozmosis Research is a full-service Clinical Trials Management Company (CRO) providing end-to-end oncology clinical trial services. The company offers a unified portfolio of service modules covering the complete clinical trial lifecycle, including concept development, project and site management, regulatory services, medical services, data management, and on-site monitoring. As an accredited Medidata Rave EDC partner, the company leverages electronic data capture technology for data management operations. The services are customizable to client requirements and designed specifically for Phase I, II, and III oncology clinical trials, with key strengths in initiating and managing complex national and multi-national trials, bench-to-bedside drug development, project management for complex research projects, and site management and monitoring.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Management Services Full-service management of Phase I, II, and III oncology clinical trials for pharmaceutical companies, biotechnology companies, academic institutions, and clinical investigators. Services include concept development, project management, site management, and study conduct oversight from study design through to analysis.
• Clinical Data Management Services Protocol-specific eCRF design and development, database building, and data management services delivered via the accredited Medidata Rave EDC (Electronic Data Capture) platform for oncology clinical trials.
• Regulatory Services Regulatory affairs support for clinical trial submissions and compliance with North American regulations, provided to sponsors and investigators running oncology studies.
• Medical Monitoring and Site Monitoring Medical monitoring, on-site monitoring, and clinical site management services conducted in accordance with ICH GCP guidelines for oncology clinical trials.
• Quality Assurance Program Quality assurance services including quality metrics, SOPs, process reviews and improvements, quality control, document control, quality assurance audits, and training for clinical trial operations.

Quantifiable outcome

• 100% of sites and sponsors indicated it was clear who to contact at Ozmosis when they had a question or concern (from Ozmosis Customer Satisfaction Survey)

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Princess Margaret Cancer Centre (Drug Development Program)coreStrategic or Co-development PartnerOzmosis is a spin out of the Drug Development Program from Princess Margaret Cancer Centre. CEO Dr. Amit Oza serves as Medical Director of the Clinical Cancer Research Unit at Princess Margaret Cancer Centre and Co-Director of the Robert and Maggie Bras and Family Drug Development Program. This is the largest new drug development program in Canada and the only centre outside the US to have a contract with the NIH for Early Phase Therapeutic studies.
• University Health Network (UHN)coreStrategic or Co-development PartnerUHN is represented on Ozmosis's Board of Directors through Suranga Fernando (Senior Director of Finance) and Arjeta Meneri (Senior Legal Counsel). Ozmosis spun out from Princess Margaret Cancer Centre which is part of UHN.
• Ontario Institute for Cancer Research (OICR)coreStrategic or Co-development PartnerOICR is represented on Ozmosis's Board of Directors through Dr. Christine Williams (Deputy Director). OICR is Ontario's cancer research institute focused on translational research programs.
• Weston Family FoundationcoreStrategic or Co-development PartnerWeston Family Foundation (encompassing the Weston Brain Institute) is represented on Ozmosis's Board of Directors through Dr. Jeffrey Coull (Head of Strategic Initiatives). The foundation supports strategic initiatives in health research.
• MedidatacoreTechnology or IntegrationOzmosis is an accredited Medidata Rave EDC (Electronic Data Capture) partner. They develop protocol-specific eCRFs and eCRF guidelines using Medidata's EDC platform for clinical trials.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Medpace: Mid-sized full-service CRO with a strong oncology therapeutic franchise and Phase I–III capabilities. Directly comparable to Ozmosis in service mix (project management, data management, regulatory, monitoring) and oncology focus, though at substantially greater scale.
• PSI CRO: Privately held full-service CRO with oncology and hematology specialty and Phase I–III capabilities. Closest match to Ozmosis in operating model — privately held, therapeutically focused, mid-sized — making it a directly comparable peer for sponsor selection.
• Worldwide Clinical Trials: Mid-sized global CRO with notable oncology and CNS focus providing project management, clinical monitoring, data management, and regulatory services. Comparable to Ozmosis as a therapeutically-specialized mid-tier CRO competing for similar Phase I/II oncology work.
• Theradex Systems: Specialty oncology CRO providing full-service Phase I–IV clinical trial management with deep oncology expertise. Most directly comparable peer in terms of therapeutic narrowness and operational model to a boutique oncology CRO like Ozmosis.

Broad incumbents

• IQVIA: Largest global CRO and clinical technology provider with broad oncology capabilities across all phases. Competes with Ozmosis for enterprise oncology trial work but operates at fundamentally greater scale with broader therapeutic and geographic coverage.
• Labcorp Drug Development (formerly Covance): Large global CRO offering Phase I–IV oncology clinical trial services alongside central labs and diagnostics. Comparable as a competing bidder for full-service oncology trials but with materially greater scale and integrated lab capabilities.
• ICON plc: Global full-service CRO with significant oncology franchise following the PRA Health Sciences merger. Competes with Ozmosis for sponsor oncology work, particularly in late-stage programs requiring global reach.
• Parexel: Global full-service CRO with strong oncology and early-phase development capabilities following its 2021 take-private. Comparable service offering across Phase I–III oncology trials, competing for the same sponsor R&D budgets.
• Syneos Health: Large global biopharmaceutical services organization offering full-service clinical development including oncology. Competes with Ozmosis for outsourced Phase I–III oncology programs, particularly from mid-sized biopharma sponsors.

Emerging players

• Novella Clinical (now part of IQVIA): Historically an oncology-specialty CRO focused on early-phase oncology trials before its acquisition by IQVIA. Reflects the niche oncology CRO segment that Ozmosis occupies and the typical exit/roll-up path for specialty oncology CROs at scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ozmosisresearch
• Facebookfacebook.com/1448106575209716
• LinkedInlinkedin.com/company/ozmosis-research-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ozmosis Research